BG Pulse Journal USA
ISSN:1947-2536 http://www.bgpulseusa.com/index.php/bg
BG PULSE JOURNAL

ALZHEIMER'S DISEASE: PATHOGENESIS, CLINICAL MANIFESTATIONS, EARLY DIAGNOSIS, AND EMERGING THERAPEUTIC APPROACHES

4th-year students of the Faculty of General Medicine,

Tirkashev Adxam Uktamjonovich

Iskandarova Bahora Bektosh kizi

Ergasheva Fotima Anvar kizi

2th-year student of the Faculty of Pediatrics,

Murodillayeva Ruxshona Jasurbek kizi

Samarkand State Medical University

https://doi.org/10.5281/zenodo.20596920

Abstract: Alzheimer's disease (AD) is the most common cause of dementia and represents a major global health challenge due to the aging population. It is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, behavioral disturbances, and loss of functional independence. The disease develops gradually over many years before clinical symptoms become apparent, making early diagnosis particularly important. Although the exact etiology remains incompletely understood, advances in neuroscience have significantly improved our understanding of the molecular mechanisms underlying the disease. This article reviews the pathogenesis of Alzheimer's disease, discusses its clinical manifestations, highlights current approaches to early diagnosis, and examines emerging therapeutic strategies aimed at slowing disease progression and improving patient outcomes.

Keywords: Alzheimer's disease; dementia; neurodegeneration; amyloid-beta; tau protein; cognitive impairment; early diagnosis; biomarkers; emerging therapies.

Introduction

Alzheimer's disease is a chronic progressive neurodegenerative disorder that primarily affects older adults and is responsible for the majority of dementia cases worldwide. As global life expectancy continues to increase, the prevalence of Alzheimer's disease is expected to rise substantially, creating significant medical, social, and economic challenges.

The disease is characterized by gradual deterioration of memory, thinking abilities, language, and executive functions. These impairments eventually interfere with daily activities and lead to complete dependence on caregivers. Beyond its impact on patients, Alzheimer's disease places a considerable burden on families, healthcare systems, and society as a whole.

Although no definitive cure currently exists, ongoing research has improved understanding of disease mechanisms and facilitated the development of innovative diagnostic and therapeutic approaches.

Pathogenesis of Alzheimer's Disease

The pathogenesis of Alzheimer's disease is complex and multifactorial. Several biological processes contribute to neuronal dysfunction and progressive cognitive decline.

One of the hallmark pathological features of Alzheimer's disease is the accumulation of amyloid-beta peptides in the brain. These peptides aggregate to form extracellular plaques that disrupt neuronal communication and trigger inflammatory responses. Chronic neuroinflammation further contributes to neuronal injury and disease progression.

Another characteristic feature is the abnormal accumulation of hyperphosphorylated tau protein within neurons. Tau proteins normally stabilize microtubules, which are essential for intracellular transport. In Alzheimer's disease, abnormal tau aggregation leads to the formation of neurofibrillary tangles, impairing neuronal function and promoting cell death.

Oxidative stress, mitochondrial dysfunction, vascular abnormalities, and impaired protein clearance mechanisms also contribute to neurodegeneration. Genetic factors play an important role, particularly in early-onset familial forms of the disease. Certain genetic variants increase susceptibility to late-onset Alzheimer's disease by influencing amyloid metabolism and neuronal resilience.

The interaction of these pathological processes ultimately results in widespread neuronal loss, brain atrophy, and progressive cognitive impairment.

Clinical Manifestations

The clinical presentation of Alzheimer's disease develops gradually and typically progresses through several stages.

The earliest symptom is usually memory impairment, particularly difficulty remembering recently acquired information. Patients may repeatedly ask the same questions, forget appointments, or misplace personal belongings. Initially, these changes may be subtle and mistaken for normal aging.

As the disease progresses, cognitive deficits become more pronounced. Language disturbances, impaired problem-solving abilities, disorientation, and reduced executive functioning increasingly interfere with daily activities. Patients may struggle with financial management, medication adherence, and navigation in familiar environments.

Behavioral and psychological symptoms frequently emerge during the course of the disease. Anxiety, depression, irritability, apathy, sleep disturbances, and agitation are common and can significantly affect quality of life.

In advanced stages, patients become dependent on caregivers for basic activities such as eating, dressing, and personal hygiene. Severe cognitive impairment, loss of communication abilities, and physical frailty characterize the terminal phase of the disease.

Importance of Early Diagnosis

Early diagnosis has become a major focus in Alzheimer's disease research and clinical practice. Identifying the disease during its earliest stages allows timely intervention, patient education, and long-term care planning.

Traditional diagnosis has largely relied on clinical evaluation and neuropsychological testing. Assessment of memory, attention, language, and executive functions remains essential for identifying cognitive impairment.

Advances in neuroimaging have improved diagnostic accuracy. Structural imaging techniques can detect brain atrophy, while functional imaging methods provide information about metabolic and pathological changes within the brain.

Biomarker research has revolutionized the field by enabling earlier detection of pathological processes before significant clinical symptoms develop. Analysis of biological markers associated with amyloid and tau pathology offers valuable insights into disease progression and may facilitate more precise diagnosis.

Early recognition also allows healthcare providers to address modifiable risk factors and implement supportive interventions that may improve patient outcomes.

Current and Emerging Therapeutic Approaches

The management of Alzheimer's disease currently focuses on symptom control, preservation of cognitive function, and maintenance of quality of life. Existing pharmacological treatments provide modest symptomatic benefits but do not completely halt disease progression.

Recent advances in neuroscience have stimulated the development of disease-modifying therapies targeting underlying pathological mechanisms. Novel therapeutic approaches aim to reduce amyloid accumulation, prevent tau aggregation, and modulate neuroinflammatory processes.

Immunotherapy has emerged as a promising area of research. Monoclonal antibodies designed to target amyloid-beta proteins seek to enhance their clearance from the brain and potentially slow disease progression. Although results remain under investigation, these therapies represent an important step toward more targeted treatment strategies.

Non-pharmacological interventions also play a critical role in patient care. Cognitive stimulation, physical activity, social engagement, and management of cardiovascular risk factors may contribute to maintaining cognitive function and overall well-being.

Emerging technologies, including artificial intelligence and precision medicine approaches, may further improve individualized treatment strategies and facilitate earlier therapeutic intervention.

Future Perspectives and Challenges

Despite significant scientific progress, Alzheimer's disease remains one of the most challenging neurological disorders to diagnose and treat. Continued research is needed to better understand disease mechanisms and identify effective preventive strategies.

One of the major future goals is the development of reliable screening tools capable of identifying individuals at risk before significant neurodegeneration occurs. Advances in biomarker

technology and genomic research may facilitate earlier intervention and personalized treatment approaches.

The growing prevalence of Alzheimer's disease also highlights the importance of healthcare planning, caregiver support, and public health initiatives aimed at reducing disease burden. Addressing these challenges will require collaboration among researchers, healthcare professionals, policymakers, and communities worldwide.

Conclusion

Alzheimer's disease is a progressive neurodegenerative disorder that represents a major global health concern. The disease is characterized by complex pathological processes involving amyloid-beta accumulation, tau pathology, neuroinflammation, and neuronal loss. These mechanisms lead to progressive cognitive decline, functional impairment, and reduced quality of life.

Early diagnosis and intervention are essential for improving patient management and facilitating future disease-modifying treatments. Although current therapies primarily provide symptomatic relief, emerging therapeutic approaches offer promising opportunities for altering disease progression.

Continued scientific research, technological innovation, and comprehensive healthcare strategies will be critical in addressing the growing burden of Alzheimer's disease and improving outcomes for affected individuals and their families.

References

Uzbek Literature

1.Rahimov, R.A. Nevrologiya. Toshkent: Yangi asr avlodi, 2021.

2.Mamatqulov, M.A. Patologik fiziologiya. Toshkent: Fan va texnologiya, 2018.

3.Karimov, H.Q. Geriatriya va gerontologiya asoslari. Toshkent: Abu Ali ibn Sino nomidagi Tibbiyot nashriyoti, 2020.

International Literature

1.Alzheimer's Association. 2025 Alzheimer's Disease Facts and Figures. Chicago, 2025.

2.National Institute on Aging. Alzheimer's Disease Research and Clinical Guidelines. Bethesda, 2024.